Clarity Pharmaceuticals Ltd (CU6)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 1.675 |
|---|---|
| 52-week range | 1.655 – 5.140 |
| Return, 1 month / 3 months | −22.5% / −28.4% |
| Return, 1 year / 3 years | −65.1% / +64.2% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 77.4% |
| Worst drawdown (1 year) | -65.8% |
| Average daily value traded | 4.87M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Clarity Pharmaceuticals is an Australian radiopharmaceutical company that develops targeted therapies and imaging agents built around copper isotopes. Its products pair a radioactive copper isotope for diagnosis with a related one for treatment, an approach known as theranostics. The company's programmes address cancers such as prostate cancer and neuroblastoma, and its customers and collaborators are clinicians, hospitals and research institutions involved in nuclear medicine. Clarity Pharmaceuticals is based in Sydney, Australia.
On this site Clarity Pharmaceuticals Ltd appears as a stock on the Australian Securities Exchange (Australia), code CU6, with prices in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Clarity Pharmaceuticals Ltd (CU6) trades on the Australian Securities Exchange in Australia. It last closed at AUD 1.675 on 22 October 2026.
Its price-based Market X-Ray is 36 out of 100 (a weak price profile), ranking 1,251 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 65.1% and over the last three months it fell 28.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 21 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -37.9% | ||
| From 52-week high | -65.8% | ||
| Momentum | 17 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -28.4% | ||
| 6-month return | -42.8% | ||
| 12-month return, skipping the last month | -55.0% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 77.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -65.8% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 4.87M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −3.2% |
|---|---|
| 1 month | −22.5% |
| 3 months | −28.4% |
| 6 months | −42.8% |
| 1 year | −65.1% |
| 3 years | +64.2% |
| 5 years | +48.2% |
Signals
| 50-day / 200-day average | 2.165 / 2.695 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.117 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.